Latest Asx News

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.

Advance ZincTek Limited has reported a remarkable turnaround for the year ended June 2025, with revenue climbing nearly 25% and net profit soaring over 230%, signaling renewed strength in its zinc mining operations.

SenSen Networks has reported a strong financial turnaround in FY2025, driven by rapid expansion in North America and innovative AI kerb enforcement technology. The company’s improved margins and positive cash flow signal a promising outlook for its Smart Cities strategy.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Alligator Energy Limited offers Placement Participants up to 278 million options exercisable at $0.047 each, following a $17.25 million placement completed in June 2025. The options offer closes on 8 September 2025 and is exclusive to Placement Participants.

IMEXHS reported a steady first half of FY25 with revenue up 4% and annualised recurring revenue climbing 11%, driven by strong adoption of its Aquila+ radiology platform and strategic capital raising.

Alligator Energy has lodged a Prospectus for Placement Options following its June 2025 capital raise, setting the stage for potential shareholder dilution and future funding opportunities.

Spacetalk Ltd reported a transformative FY25 with a 25% increase in annual recurring revenue and a significant narrowing of losses, underpinned by strong subscriber growth and a strategic debt restructuring.

Phoslock Environmental Technologies reports a sharp revenue increase driven by Brazil and international markets, yet continues to face significant losses and ongoing legal challenges.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Resonance Health Limited reported a 29% revenue increase to $11.07 million for FY25 but posted a net loss of $1.73 million, reflecting strategic investments and expansion in clinical trial services.